Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Hyperlipidemia Stories

2014-02-12 08:29:41

New Published Study Reveals BergaMet(TM) Added to Statins Enhances Lipid Lowering and Artery Health DENVER, Feb. 12, 2014 /PRNewswire/ -- New published research reveals that a highly concentrated proprietary extract of the Calabrian bergamot fruit called BergaMet(TM) (38% citrus bergamot extract, NathealthSolutions) enhances the effect of the lipid lowering drug rosuvastatin (Crestor(TM)) when given to patients with elevated cholesterol. Led by cardiologists Franco Romeo and Vincenzo Mollace,...

2014-02-04 11:23:37

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues. Patients with type 2 diabetes (T2DM) are at increased risk for decline in cognitive function, for reduced brain volume and increased white matter lesions on brain imaging,...

2013-12-05 08:29:55

CAMBRIDGE, Mass., Dec. 5, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced the initiation of a Phase 2 clinical trial investigating the safety and efficacy of CAT-2003 in patients with severe hypertriglyceridemia, defined as serum triglyceride levels of 500 mg/dL or greater. CAT-2003 is a conjugate of niacin and the omega 3 fatty acid, eicosapentaenoic acid (EPA), employing Catabasis' proprietary SMART Linker technology. In this second Phase 2 trial of CAT-2003,...

2013-08-28 08:26:32

-- Catabasis CMO to Present at PACE Conference in Amsterdam -- CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that new clinical data on the inhibition of PSCK9* by its oral SMART Linker conjugate, CAT-2003, will be presented at the Physicians Academy for Continuing Education (PACE) conference in Amsterdam on Aug. 31 by Catabasis' chief medical officer, Joanne Donovan, M.D., Ph.D., during the "Novel interventions in cardiovascular disease:...

2013-08-21 08:25:56

CAMBRIDGE, Mass., Aug. 21, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced the initiation of PATHWAYS I*, a Phase 2 trial investigating the safety, tolerability and efficacy of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology. CAT-2003 will be evaluated in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. "We recently announced positive Phase 1 data showing...

2013-07-30 08:33:54

-- Achieves Improvements in Biomarkers PCSK9, ApoB and LDL -- CAMBRIDGE, Mass., July 30, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that preliminary data from a Phase 1 trial of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology, demonstrated a significant reduction in fasting and post-prandial triglyceride levels. CAT-2003 also had positive effects on other biomarkers, including reductions in apolipoprotein...

2013-07-29 16:25:06

DUBLIN, July 29, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/49ljmx/statins_market_to) has announced the addition of the "Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share" [http://www.researchandmarkets.com/research/49ljmx/statins_market_to ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This...

2013-07-18 12:28:01

WOODCLIFF LAKE, N.J., July 18, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release (DR) capsules. Fenofibric acid DR is the generic version of AbbVie's Trilipix(®) and is indicated: in combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD...

2013-06-17 12:28:59

Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO(®) (pitavastatin) 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin...

2013-06-06 08:29:40

PARSIPPANY, N.J., June 6, 2013 /PRNewswire/ -- Recent guidance from the American Association of Clinical Endocrinologists (AACE) highlight for the first time a cardiovascular risk factor management algorithm that identifies treatments of dyslipidemia in patients with type 2 diabetes.(1 )In these new guidelines, Welchol(®) (colesevelam HCI) is the only therapy recognized that provides patients with a dual-benefit: it helps to lower both A1C and LDL cholesterol ("bad" cholesterol or LDL-C)...